JP2012522756A5 - - Google Patents

Download PDF

Info

Publication number
JP2012522756A5
JP2012522756A5 JP2012502710A JP2012502710A JP2012522756A5 JP 2012522756 A5 JP2012522756 A5 JP 2012522756A5 JP 2012502710 A JP2012502710 A JP 2012502710A JP 2012502710 A JP2012502710 A JP 2012502710A JP 2012522756 A5 JP2012522756 A5 JP 2012522756A5
Authority
JP
Japan
Prior art keywords
cancer
lif
inhibitor
gene
glioma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012502710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012522756A (ja
JP6207836B2 (ja
Filing date
Publication date
Priority claimed from ES200900928A external-priority patent/ES2363358B1/es
Application filed filed Critical
Publication of JP2012522756A publication Critical patent/JP2012522756A/ja
Publication of JP2012522756A5 publication Critical patent/JP2012522756A5/ja
Application granted granted Critical
Publication of JP6207836B2 publication Critical patent/JP6207836B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2012502710A 2009-04-03 2010-04-06 望ましくない細胞増殖と関連する疾患の治療のための治療剤 Active JP6207836B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200900928A ES2363358B1 (es) 2009-04-03 2009-04-03 Agentes terapéuticos para el tratamiento de enfermedades asociadas con una proliferación celular indeseable.
ESP200900928 2009-04-03
PCT/EP2010/054499 WO2010115868A2 (en) 2009-04-03 2010-04-06 Therapeutic agents for the treatment of diseases associated with undesired cell proliferation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015178986A Division JP2016040255A (ja) 2009-04-03 2015-09-11 望ましくない細胞増殖と関連する疾患の治療のための治療剤

Publications (3)

Publication Number Publication Date
JP2012522756A JP2012522756A (ja) 2012-09-27
JP2012522756A5 true JP2012522756A5 (enExample) 2013-05-23
JP6207836B2 JP6207836B2 (ja) 2017-10-04

Family

ID=42342718

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2012502710A Active JP6207836B2 (ja) 2009-04-03 2010-04-06 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2015178986A Pending JP2016040255A (ja) 2009-04-03 2015-09-11 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2018152551A Pending JP2019006784A (ja) 2009-04-03 2018-08-14 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2020016672A Pending JP2020090522A (ja) 2009-04-03 2020-02-04 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2021186785A Active JP7197665B2 (ja) 2009-04-03 2021-11-17 望ましくない細胞増殖と関連する疾患の治療のための治療剤

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2015178986A Pending JP2016040255A (ja) 2009-04-03 2015-09-11 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2018152551A Pending JP2019006784A (ja) 2009-04-03 2018-08-14 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2020016672A Pending JP2020090522A (ja) 2009-04-03 2020-02-04 望ましくない細胞増殖と関連する疾患の治療のための治療剤
JP2021186785A Active JP7197665B2 (ja) 2009-04-03 2021-11-17 望ましくない細胞増殖と関連する疾患の治療のための治療剤

Country Status (24)

Country Link
US (4) US10100112B2 (enExample)
EP (2) EP3045474B1 (enExample)
JP (5) JP6207836B2 (enExample)
KR (6) KR20120100703A (enExample)
CN (2) CN107964043A (enExample)
AU (1) AU2010233791B2 (enExample)
BR (1) BRPI1015369A2 (enExample)
CA (1) CA2757680C (enExample)
CY (1) CY1124148T1 (enExample)
DK (1) DK3045474T3 (enExample)
EA (1) EA201101450A1 (enExample)
ES (2) ES2363358B1 (enExample)
HR (1) HRP20210352T1 (enExample)
HU (1) HUE054196T2 (enExample)
IL (1) IL215467A (enExample)
LT (1) LT3045474T (enExample)
MX (1) MX336903B (enExample)
PL (1) PL3045474T3 (enExample)
PT (1) PT3045474T (enExample)
SG (2) SG10202010568RA (enExample)
SI (1) SI3045474T1 (enExample)
SM (1) SMT202100153T1 (enExample)
WO (1) WO2010115868A2 (enExample)
ZA (1) ZA201107215B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ565172A (en) * 2005-07-19 2012-12-21 Stemgen S P A Inhibition of the tumorigenic potential of tumor stem cells by LIF and BMPS
EP2371860A1 (en) 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
JP2015071566A (ja) * 2013-10-03 2015-04-16 住友ベークライト株式会社 Ｆｇｆ４遺伝子増幅腫瘍の医薬組成物
CA2941703A1 (en) * 2014-03-11 2015-09-17 Godavari Biorefineries Limited Cancer stem cell targeting compounds
KR102503476B1 (ko) * 2014-06-30 2023-02-24 알토 바이오사이언스 코포레이션 Il-15-베이즈드 분자 및 이의 사용 방법
JP2017527582A (ja) * 2014-09-10 2017-09-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア Ｋ−Ｒａｓによって媒介されるシグナリング経路および悪性疾患の抗ｈＬＩＦ抗体によるターゲティング方法
EP3067422B1 (en) * 2015-03-13 2024-07-31 Sabanci Üniversitesi Ct-1 inhibitors
WO2016154203A1 (en) 2015-03-23 2016-09-29 Evestra, Inc. Novel cytotoxic agents that preferentially target leukemia inhibitory factor (lif) for the treatment of malignancies and as new contraceptive agents
EP3173483A1 (en) 2015-11-27 2017-05-31 Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron Agents for the treatment of diseases associated with undesired cell proliferation
US10583191B2 (en) 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof
SI3555132T1 (sl) 2016-12-19 2024-04-30 Medimmune Limited Protitelesa proti LIF in njihove uporabe
SG11202011170YA (en) * 2018-05-14 2020-12-30 Medimmune Ltd Antibodies against lif and dosage forms thereof
EP3806899A2 (en) * 2018-06-18 2021-04-21 MedImmune Limited Combination of lif inhibitors and platinum-based antineoplastic agents for use in treating cancer
KR20210024007A (ko) * 2018-06-18 2021-03-04 메디뮨 리미티드 암이 있는 개체에서 항-lif 항체 치료에 대한 반응을 개선하기 위한 방법
WO2020056349A2 (en) * 2018-09-13 2020-03-19 Evestra, Inc. Lif/lifr antagonist oncology and nonmalignant diseases
WO2020213665A1 (ja) * 2019-04-17 2020-10-22 国立大学法人広島大学 Ｉｌ－６阻害剤及びｃｃｒ２阻害剤を組み合わせて投与することを特徴とする泌尿器がんの治療剤
CN111020030A (zh) * 2019-12-03 2020-04-17 中山大学 一种骨肉瘤干细胞标志物及其应用、试剂盒
EP3988116A1 (en) * 2020-10-23 2022-04-27 Consejo Superior De Investigaciones Científicas (CSIC) Methods and compositions for the treatment of hematologic malignancies
CN120507517B (zh) * 2025-05-21 2026-04-10 浙江省肿瘤医院 用于评估宫颈癌鳞癌和腺癌特异性的预后分子标记物及其应用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902505A (en) 1986-07-30 1990-02-20 Alkermes Chimeric peptides for neuropeptide delivery through the blood-brain barrier
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
AU632993B2 (en) 1987-12-15 1993-01-21 Gene Shears Pty. Limited Ribozymes
US5176996A (en) 1988-12-20 1993-01-05 Baylor College Of Medicine Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
US5256775A (en) 1989-06-05 1993-10-26 Gilead Sciences, Inc. Exonuclease-resistant oligonucleotides
US5264564A (en) 1989-10-24 1993-11-23 Gilead Sciences Oligonucleotide analogs with novel linkages
GB9004890D0 (en) * 1990-03-05 1990-05-02 Heath John K Leukaemia inhibitory factor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
JPH05304986A (ja) * 1992-04-28 1993-11-19 Tosoh Corp ｇｐ１３０蛋白質に対するモノクロ−ナル抗体
AU4231393A (en) 1992-05-08 1993-12-13 Genentech Inc. Antibodies to leukemia inhibitory factor
GB9413316D0 (en) 1994-07-01 1994-08-24 Cancer Res Campaign Tech Novel proteins
US6251588B1 (en) 1998-02-10 2001-06-26 Agilent Technologies, Inc. Method for evaluating oligonucleotide probe sequences
US20050147609A1 (en) 1998-05-15 2005-07-07 Genentech, Inc. Use of anti-IL-17 antibody for the treatment of cartilage damaged by osteoarthritis
KR100940380B1 (ko) 1999-01-15 2010-02-02 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
EP1156823B1 (en) * 1999-02-12 2008-10-29 The Scripps Research Institute Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
US7084257B2 (en) 2001-10-05 2006-08-01 Amgen Inc. Fully human antibody Fab fragments with human interferon-gamma neutralizing activity
WO2003085093A2 (en) 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
EP1576131A4 (en) * 2002-08-15 2008-08-13 Genzyme Corp EXPRESSION PATTERN IN BRAIN DENTHELIC CELLS
US20060078533A1 (en) * 2004-10-12 2006-04-13 Omoigui Osemwota S Method of prevention and treatment of aging and age-related disorders including atherosclerosis, peripheral vascular disease, coronary artery disease, osteoporosis, arthritis, type 2 diabetes, dementia, alzheimer's disease and cancer
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
US20040248158A1 (en) * 2003-01-28 2004-12-09 Loughran Thomas P Differentially expressed genes in large granular lymphocyte leukemia
WO2005030803A1 (en) * 2003-09-29 2005-04-07 The Walter And Eliza Hall Institute Of Medical Research Therapeutic molecules
EP1752536A4 (en) * 2004-05-11 2008-04-16 Alphagen Co Ltd POLYNUCLEOTIDE CAUSING RNA INTERFERENCE AND METHOD OF REGULATING GENE EXPRESSION WITH THE USE OF THE SAME
CA2734172A1 (en) * 2008-08-29 2010-03-04 Genentech, Inc. Diagnostics and treatments for vegf-independent tumors
EP2371860A1 (en) * 2010-04-05 2011-10-05 Fundació Privada Institut d'Investigació Oncològica de Vall d'Hebron Antibody recognising human leukemia inhibitory factor (LIF) and use of anti-LIF antibodies in the treatment of diseases associated with unwanted cell proliferation
US10583191B2 (en) * 2016-12-19 2020-03-10 Mosaic Biomedicals Slu Antibodies against LIF and uses thereof

Similar Documents

Publication Publication Date Title
JP6946385B2 (ja) 乳がん転移の診断、予後診断、および処置のための方法
CN105980576B (zh) 用于源自乳腺癌的骨转移癌的预后和治疗的方法
ES2647762T3 (es) Métodos de uso de un nuevo receptor de eritropoyetina protector de tejido (NEPOR)
EP2650682A1 (en) Method for the prognosis and treatment of cancer metastasis
JP2018078911A5 (enExample)
JP2015521050A5 (enExample)
JP2016105731A5 (enExample)
WO2014072517A1 (en) Methods and kits for the prognosis of colorectal cancer
PT2492355E (pt) Recetor de eritropoietina protetora de tecido (nepor) e métodos de utilização
CN101946008A (zh) 用于控制血管生成的方法
KR20190093691A (ko) 바람직하지 않은 세포 증식과 관련된 질환의 치료를 위한 치료제
Simile et al. Post-translational deregulation of YAP1 is genetically controlled in rat liver cancer and determines the fate and stem-like behavior of the human disease
Ge et al. Circulating endothelial progenitor cell: a promising biomarker in clinical oncology
KR20170141951A (ko) Nckap1을 유효성분으로 포함하는 대장암 진단 또는 대장암 전이 예후 예측용 바이오마커 조성물
JP2008525479A5 (enExample)
US20140296098A1 (en) Diagnostic and Prognostic Markers for Cancer
WO2020082037A1 (en) Methods for treating a subtype of small cell lung cancer
JP6397765B2 (ja) プロテアソーム阻害剤に応答するバイオマーカー
AU2008222602B2 (en) A target for breast cancer therapy and/or diagnosis
WO2011129427A9 (ja) 癌の診断剤および治療剤
Jaszczynska-Nowinka et al. Expression of SDF-1 and CXCR4 transcript variants and CXCR7 in epithelial ovarian cancer
AU2008357875A1 (en) Interferon Epsilon (IFNE1) as a marker for targeted cancer therapy
CN105838797B (zh) 一种诊治食管癌的分子标志物
KR20190059237A (ko) Pmvk를 유효성분으로 포함하는 방사선 저항성 암 진단용 또는 방사선 치료 예후 예측용 바이오마커 조성물
JP2008525005A5 (enExample)